RxDoctor Payments DataLook up a doctor →

Alvin Burstein, MD

Psychiatry · Scottsdale, AZNPI 1962553412

Payments from drug & device makers

$18,051in general payments, 2019–2025

Across 685 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • AbbVie$4K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$946
  • Lundbeck LLC$710
  • plus $6K from 28 others

What the payments were for

  • Consulting fees$3502%
  • Speaking & faculty fees$4,89027%
  • Travel & lodging$410%
  • Food & beverage$12,51969%
  • Education$2521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,051 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.

See all psychiatry providers in Arizona

Medicare billing

Part B allowed, 2024
$304,166
Medicare patients
389
Services billed
2,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl43$90,959
CaplytaLumateperone Tosylate21$36,701
NuedextaDextromethorphan Hbr/Quinidine14$31,181
LybalviOlanzapine/Samidorphan Malate15$27,222
BelsomraSuvorexant20$16,185
AuvelityDextromethorphan Hbr/Bupropion12$11,858
Lamotrigine411$6,155
Quetiapine Fumarate272$4,840
Lurasidone Hcl42$4,509
ViibrydVilazodone Hcl12$4,300
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$4,040
Aripiprazole99$3,382
Venlafaxine Hcl ErVenlafaxine Hcl127$3,245
Bupropion XlBupropion Hcl113$3,183
Duloxetine Hcl150$2,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Viibryd$3,722$95,25855 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,778$36,70121 claims
Avanir Pharmaceuticals, Inc.Nuedexta$611$31,18114 claims
Alkermes, Inc.Lybalvi$577$27,22215 claims
Axsome Therapeutics, Inc.Auvelity$208$11,85812 claims
Almatica Pharma LLCSertraline Hcl$515$999103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.

Other psychiatry in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →